Positioning Crohn's Disease Therapies in the Era of Small Molecules and Combination Therapies

Overview

Journal Curr Gastroenterol Rep

Specialty Gastroenterology

Date 2024 Jul 6

PMID 38970743

Authors

Ariela K Holmer

David Hudesman

Affiliations

Soon will be listed here.

References

Hanauer S, Feagan B, Lichtenstein G, Mayer L, Schreiber S, Colombel J . Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359(9317):1541-9. DOI: 10.1016/S0140-6736(02)08512-4. View

Colombel J, Sandborn W, Reinisch W, Mantzaris G, Kornbluth A, Rachmilewitz D . Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362(15):1383-95. DOI: 10.1056/NEJMoa0904492. View

Colombel J, Adedokun O, Gasink C, Gao L, Cornillie F, DHaens G . Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis. Clin Gastroenterol Hepatol. 2018; 17(8):1525-1532.e1. DOI: 10.1016/j.cgh.2018.09.033. View

Colombel J, Sandborn W, Rutgeerts P, Enns R, Hanauer S, Panaccione R . Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132(1):52-65. DOI: 10.1053/j.gastro.2006.11.041. View

Sandborn W, Feagan B, Rutgeerts P, Hanauer S, Colombel J, Sands B . Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013; 369(8):711-21. DOI: 10.1056/NEJMoa1215739. View

Sands B, Feagan B, Rutgeerts P, Colombel J, Sandborn W, Sy R . Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014; 147(3):618-627.e3. DOI: 10.1053/j.gastro.2014.05.008. View

Sandborn W, Baert F, Danese S, Krznaric Z, Kobayashi T, Yao X . Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology. 2019; 158(3):562-572.e12. DOI: 10.1053/j.gastro.2019.08.027. View

Vermeire S, DHaens G, Baert F, Danese S, Kobayashi T, Loftus E . Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial. J Crohns Colitis. 2021; 16(1):27-38. PMC: 8797168. DOI: 10.1093/ecco-jcc/jjab133. View

Feagan B, Sandborn W, Gasink C, Jacobstein D, Lang Y, Friedman J . Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2016; 375(20):1946-1960. DOI: 10.1056/NEJMoa1602773. View

10.

Hanauer S, Sandborn W, Feagan B, Gasink C, Jacobstein D, Zou B . IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. J Crohns Colitis. 2019; 14(1):23-32. DOI: 10.1093/ecco-jcc/jjz110. View

11.

DHaens G, Panaccione R, Baert F, Bossuyt P, Colombel J, Danese S . Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022; 399(10340):2015-2030. DOI: 10.1016/S0140-6736(22)00467-6. View

12.

Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel J, Danese S . Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022; 399(10340):2031-2046. DOI: 10.1016/S0140-6736(22)00466-4. View

13.

Loftus Jr E, Panes J, Lacerda A, Peyrin-Biroulet L, DHaens G, Panaccione R . Upadacitinib Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2023; 388(21):1966-1980. DOI: 10.1056/NEJMoa2212728. View

14.

Sands B, Irving P, Hoops T, Izanec J, Gao L, Gasink C . Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022; 399(10342):2200-2211. DOI: 10.1016/S0140-6736(22)00688-2. View

15.

Singh S, Murad M, Fumery M, Sedano R, Jairath V, Panaccione R . Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2021; 6(12):1002-1014. PMC: 8933137. DOI: 10.1016/S2468-1253(21)00312-5. View

16.

Barberio B, Gracie D, Black C, Ford A . Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn's disease: systematic review and network meta-analysis. Gut. 2022; 72(2):264-274. DOI: 10.1136/gutjnl-2022-328052. View

17.

Biemans V, van der Woude C, Dijkstra G, van der Meulen-de Jong A, Lowenberg M, de Boer N . Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment. Aliment Pharmacol Ther. 2020; 52(1):123-134. PMC: 7318204. DOI: 10.1111/apt.15745. View

18.

Bressler B, Yarur A, Silverberg M, Bassel M, Bellaguarda E, Fourment C . Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study. J Crohns Colitis. 2021; 15(10):1694-1706. PMC: 8495488. DOI: 10.1093/ecco-jcc/jjab058. View

19.

Yang E, Panaccione N, Whitmire N, Dulai P, Vande Casteele N, Singh S . Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease. Aliment Pharmacol Ther. 2020; 51(11):1031-1038. PMC: 8032452. DOI: 10.1111/apt.15719. View

20.

Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C . Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005; 128(7):1805-11. DOI: 10.1053/j.gastro.2005.03.003. View